Market Research Report

A quick peek into the report

1.1 Inclusion and Exclusion Criteria

2.1 Target Audience
2.2 Key Questions Answered in the Report

3.1   Global Microbiome Therapeutics: Research Methodology
3.2   Primary Data Sources
3.3   Secondary Data Sources
3.4   Market Estimation Model
3.5   Criteria for Company Profiling

4.1 Market Size and Future Growth Potential
4.2 Historical Trends

5.1   Regulatory Landscape
5.1.1   Regulatory Requirements for Live Biotherapeutic Products (LBPs)
5.1.2   Quality Check of LBPs
5.1.3   FDA Approved Fecal Microbiota Transplantation (FMT) Quality Check Procedure
5.2   Patent Landscape
5.2.1   Patent Filing Analysis
5.2.2   Key Players Patent Portfolio
5.2.3   Key Players Patent Expiration Analysis
5.3   Partnership Landscape
5.4   Government Initiatives
5.5   Impact of COVID-19 on the Global Microbiome Therapeutics Market
5.5.1   Clinical Trial Disruptions and Resumptions

6.1   Market Drivers
6.1.1   Growing Strategic Activities in Microbiome Therapeutics Segment
6.1.2   Potential of Microbiome Therapeutics to Address Unmet Needs of Existing Treatment Options
6.1.3   Microbiome Therapeutic Products as a Safer Alternative to Conventional Drug Treatments
6.2   Market Restraints
6.2.1   Lack of Uniformed Standardized Regulatory Guidelines
6.2.2   Associated Safety Issues with LBPs
6.2.3   Storage Issues with Live Micro-Organisms
6.2.4   Challenges Associated with Manufacturing of LBPs
6.3   Market Opportunities
6.3.1   Need for Current Good Manufacturing Practice (cGMP) Certified Contract Manufacturing Facilities
6.3.2   Growing Disease Dimension
6.3.3   Entry of Major Players

7.1   Microbiome Therapeutics Pipeline Landscape
7.1.1   Competitive Landscaping
7.1.2   Pipeline Analysis
7.1.2.1   By Development Phase
7.1.2.2   By Route of Administration
7.1.2.3   By Type of Microbiome Strategy
7.1.2.4   By Indication
7.1.3   Emerging Microbiome Therapeutics Products
7.2   Probable Potential First Entrants to Global Microbiome Therapeutics Market/ Microbiome Therapeutics Clinical Trial Design
7.2.1   CP-101 (Finch Therapeutics Group, Inc.)
7.2.1.1   CP-101: Product Profile
7.2.2   SER-109 (Seres Therapeutics, Inc.)
7.2.2.1   SER-109: Product Profile
7.2.3   RBX-2660 (Rebiotix Inc.)
7.2.3.1   RBX-2660: Product Profile
7.2.4   CH-106 (Caelus Health)
7.2.4.1   CH-106: Product Profile
7.2.5   LACTIN-V (Osel Inc.)
7.2.5.1   LACTIN-V: Product Profile
7.2.6   MaaT013 (MaaT Pharma)
7.2.6.1   MaaT013: Product Profile

8.1   Key Strategies and Developments
8.2   Synergistic Activities
8.3   Product Launch and Regulatory Approvals
8.4   Funding and Investment
8.5   Mergers and Acquisitions
8.6   Market Share Analysis
8.7   Growth-Share Analysis (Opportunity Mapping)
8.7.1   By Region
8.7.2   By Company

9.1   Overview
9.2   Gastrointestinal and Infectious Diseases
9.3   Skin Disorders
9.4   Cancer Indications
9.5   Other Indications

10.1   Overview
10.2   North America
10.2.1   Overview
10.2.2   U.S.
10.2.3   Canada
10.3   Europe
10.3.1   Overview
10.3.2   France
10.3.3   Germany
10.3.4   Sweden
10.3.5   U.K.
10.3.6   Italy
10.3.7   Spain
10.3.8   Rest-of-Europe
10.4   Asia-Pacific (APAC)
10.4.1   Overview
10.4.2   Japan
10.4.3   Australia
10.4.4   China
10.4.5   India
10.4.6   Rest-of-Asia-Pacific
10.5   Rest-of-the-World
10.5.1   Overview

11.1   4D pharma plc
11.1.1   Company Overview
11.1.2   Role of 4D pharma plc in the Global Microbiome Therapeutics Market
11.1.3   Key Competitors of the Company
11.1.4   Financials
11.1.5   Recent Developments
11.1.6   Analyst’s Perspective
11.2   Seres Therapeutics, Inc.
11.2.1   Company Overview
11.2.2   Role of Seres Therapeutics, Inc. in the Global Microbiome Therapeutics Market
11.2.3   Key Competitors of the Company
11.2.4   Financials
11.2.5   Recent Developments
11.2.6   Analyst Perspective
11.3   Microbiotica
11.3.1   Company Overview
11.3.2   Role of Microbiotica in the Global Microbiome Therapeutics Market
11.3.3   Key Competitors of the Company
11.3.4   Recent Developments
11.3.5   Analyst’s Perspective
11.4   Enterome
11.4.1   Company Overview
11.4.2   Role of Enterome in the Global Microbiome Therapeutics Market
11.4.3   Key Competitors of the Company
11.4.4   Recent Developments
11.4.5   Analyst’s Perspective
11.5   Destiny Pharma plc
11.5.1   Company Overview
11.5.2   Role of Destiny Pharma plc in the Global Microbiome Therapeutics Market
11.5.3   Key Competitors of the Company
11.5.4   Financials
11.5.5   Recent Developments
11.5.6   Analyst’s Perspective
11.6   Taisho Pharmaceutical Holdings
11.6.1   Company Overview
11.6.2   Role of Taisho Pharmaceutical Holdings in the Global Microbiome Therapeutics Market
11.6.3   Key Competitors of the Company
11.6.4   Financials
11.6.5   Recent Developments
11.6.6   Analyst’s Perspective
11.7   AOBiome Therapeutics, Inc.
11.7.1   Company Overview
11.7.2   Role of AOBiome Therapeutics, Inc. in the Global Microbiome Therapeutics Market
11.7.3   Key Competitors of the Company
11.7.4   Recent Developments
11.7.5   Analyst’s Perspective
11.8   Finch Therapeutics Group, Inc.
11.8.1   Company Overview
11.8.2   Role of Finch Therapeutics Group, Inc. in the Global Microbiome Therapeutics Market
11.8.3   Key Competitors of the Company
11.8.4   Financials
11.8.5   Recent Developments
11.8.6   Analyst’s Perspective
11.9   Ferring Pharmaceuticals
11.9.1   Company Overview
11.10 Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
11.10.1   Company Overview
11.10.2   Role of Rebiotix Inc. in the Global Microbiome Therapeutics Market
11.10.3   Key Competitors of the Company
11.10.4   Recent Developments
11.10.5   Analyst’s Perspective
11.11   MaaT Pharma
11.11.1   Company Overview
11.11.2   Role of MaaT Pharma in the Global Microbiome Therapeutics Market
11.11.3   Key Competitors of the Company
11.11.4   Financials
11.11.5   Recent Developments
11.11.6   Analyst’s Perspective
11.12   Vedanta Biosciences Inc.
11.12.1   Company Overview
11.12.2   Role of Vedanta Biosciences Inc. in the Global Microbiome Therapeutics Market
11.12.3   Key Competitors of the Company
11.12.4   Recent Developments
11.12.5   Analyst’s Perspective
11.13   OxThera AB
11.13.1   Company Overview
11.13.2   Role of OxThera AB in the Global Microbiome Therapeutics Market
11.13.3   Key Competitors of the Company
11.13.4   Recent Developments
11.13.5   Analyst’s Perspective
11.14   Pendulum Therapeutics
11.14.1   Company Overview
11.14.2   Role of Pendulum Therapeutics in the Global Microbiome Therapeutics Market
11.14.3   Key Competitors of the Company
11.14.4   Recent Developments
11.14.5   Analyst’s Perspective
11.15   Caelus Health
11.15.1   Company Overview
11.15.2   Role of Caelus Health in the Global Microbiome Therapeutics Market
11.15.3   Key Competitors of the Company
11.15.4   Recent Developments
11.15.5   Analyst’s Perspective
11.16   Quorum Innovations
11.16.1   Company Overview
11.16.2   Role of Quorum Innovations in the Global Microbiome Therapeutics Market
11.16.3   Key Competitors of the Company
11.16.4   Recent Developments
11.16.5   Analyst’s Perspective
11.17   Sanofi S.A.
11.17.1   Company Overview
11.17.2   Role of Sanofi S.A. in the Global Microbiome Therapeutics Market
11.17.3   Key Competitors of the Company
11.17.4   Financials
11.17.5   Recent Developments
11.17.6   Analyst’s Perspective
11.18   DermBiont, Inc.
11.18.1   Company Overview
11.18.2   Role of DermBiont, Inc. in the Global Microbiome Therapeutics Market
11.18.3   Key Competitors of the Company
11.18.4   Recent Developments
11.18.5   Analyst’s Perspective
11.19   EnteroBiotix Ltd
11.19.1   Company Overview
11.19.2   Role of EnteroBiotix Ltd in the Global Microbiome Therapeutics Market
11.19.3   Key Competitors of the Company
11.19.4   Recent Developments
11.19.5   Analyst’s Perspective
11.20 YSOPIA Bioscience
11.20.1   Company Overview
11.20.2   Role of YSOPIA Bioscience in the Global Microbiome Therapeutics Market
11.20.3   Key Competitors of the Company
11.20.4   Recent Developments
11.20.5   Analyst’s Perspective
11.21   Winclove Probiotics
11.21.1   Company Overview
11.21.2   Role of Winclove Probiotics in the Global Microbiome Therapeutics Market
11.21.3   Key Competitors of the Company
11.21.4   Recent Developments
11.21.5   Analyst’s Perspective
11.22   TargEDys
11.22.1   Company Overview
11.22.2   Role of TargEDys in the Global Microbiome Therapeutics Market
11.22.3   Key Competitors of the Company
11.22.4   Recent Developments
11.22.5   Analyst’s Perspective
11.23   Evelo Biosciences, Inc.
11.23.1   Company Overview
11.23.2   Role of Evelo Biosciences, Inc. in the Global Microbiome Therapeutics Market
11.23.3   Key Competitors of the Company
11.23.4   Financials
11.23.5   Recent Developments
11.23.6   Analyst’s Perspective
11.24   BiomX
11.24.1   Company Overview
11.24.2   Role of BiomX in the Global Microbiome Therapeutics Market
11.24.3   Key Competitors of the Company
11.24.4   Financials
11.24.5   Recent Developments
11.24.6   Analyst’s Perspective
11.25   Biomica Ltd.
11.25.1   Company Overview
11.25.2   Role of Biomica Ltd. in the Global Microbiome Therapeutics Market
11.25.3   Key Competitors of the Company
11.25.4   Recent Developments
11.25.5   Analyst’s Perspective
11.26   Scioto Biosciences, Inc.
11.26.1   Company Overview
11.26.2   Role of Scioto Biosciences, Inc. in the Global Microbiome Therapeutics Market
11.26.3   Key Competitors of the Company
11.26.4   Recent Developments
11.26.5   Analyst’s Perspective
11.27   Lactobio A/S
11.27.1   Company Overview
11.27.2   Role of Lactobio A/S in the Global Microbiome Therapeutics Market
11.27.3   Key Competitors of the Company
11.27.4   Recent Developments
11.27.5   Analyst’s Perspective

Appendix

Table 1:   Global Microbiome Therapeutics Market: Key Players Patent Portfolio
Table 2:   Patent Expiration Analysis
Table 3:   Partnership Landscaping
Table 4:   Government Initiatives in Microbiome Therapeutics
Table 5:   Impact of COVID-19 on Microbiome Therapeutics Developing Companies
Table 6:   Key Players/Investors Portfolio
Table 7:   Emerging Microbiome Therapeutics Products Pipeline
Table 8:   Probable Potential First Entrants to Global Microbiome Therapeutics Market
Table 9:   4D pharma plc: Key Competitors
Table 10:   Seres Therapeutics, Inc.: Key Competitors
Table 11:   Microbiotica: Key Competitors
Table 12:   Enterome: Key Competitors
Table 13:   Destiny Pharma plc: Key Competitors
Table 14:   Taisho Pharmaceutical Holdings: Key Competitors
Table 15:   AOBiome Therapeutics, Inc.: Key Competitors
Table 16:   Finch Therapeutics Group, Inc.: Key Competitors
Table 17:   Rebiotix Inc.: Key Competitors
Table 18:   MaaT Pharma: Key Competitors
Table 19:   Vedanta Biosciences Inc.: Key Competitors
Table 20:   Pendulum Therapeutics: Key Competitors
Table 21:   Caelus Health: Key Competitors
Table 22:   Quorum Innovations: Key Competitors
Table 23:   Sanofi S.A.: Key Competitors
Table 24:   DermBiont Inc.: Key Competitors
Table 25:   EnteroBiotix Ltd: Key Competitors
Table 26:   YSOPIA Bioscience: Key Competitors
Table 27:   Winclove Probiotics: Key Competitors
Table 28:   TargEDys: Key Competitors
Table 29:   Evelo Biosciences, Inc.: Key Competitors
Table 30:   BiomX: Key Competitors
Table 31:   Biomica Ltd.: Key Competitors
Table 32:   Scioto Biosciences, Inc.: Key Competitors
Table 33:   Lactobio A/S: Key Competitors

Figure 1:   Global Microbiome Therapeutics Market Share (by Target Therapy Area), $Million, 2021
Figure 2:   Global Microbiome Therapeutics Market Share (by Region), $Million, 2021 and 2032
Figure 3:   Growth-Share Analysis (by Region), 2020-2021
Figure 4:   Global Microbiome Therapeutics Market Segmentation
Figure 5:   Global Microbiome Therapeutics Market Methodology
Figure 6:   Primary Research Methodology
Figure 7:   Bottom-Up Approach (Segment Wise Analysis)
Figure 8:   Top-Down Approach (Segment-Wise Analysis)
Figure 9:   Global Microbiome Therapeutics Market, $Million, 2021-2032
Figure 10:   Historical Evolution of Microbiome Therapeutics
Figure 11:   Chemistry, Manufacturing, and Control (CMC) Information of LBPs by FDA
Figure 12:   Patent Landscape of the Microbiome Therapeutics Market (by Region), 2019-2021
Figure 13:   COVID-19 Impact on the Global Microbiome Therapeutics Market
Figure 14:   Number of Strategic Activities in the Global Microbiome Therapeutics Market, 2019-2021
Figure 15:   Number of Agreements for Leading Companies
Figure 16:   Share of Microbiome Therapeutics Products in Global Clinical Trials (by Development Phase)
Figure 17:   Share of Microbiome Therapeutics Pipeline Candidates (by Route of Administration)
Figure 18:   Share of Microbiome Therapeutics Products (by Type of Microbiome Strategy)
Figure 19:   Number of Microbiome Therapeutic Products in Global Clinical Trials (by Indication)
Figure 20:   CP-101: Phase II Clinical Design for Recurrent C. diff. Infection (CDI)
Figure 21:   CP-101 Phase III Clinical Design for Recurrent C. diff. Infection (CDI)
Figure 22:   SER-109: Mechanism of Action
Figure 23:   SER-109: Clinical Trial Details for Recurrent C. diff. Infection (CDI)
Figure 24:   RBX-2660: Key Regulatory Milestones
Figure 25:   RBX-2660: Clinical Progress for Recurrent C. Diff Infection (CDI)
Figure 26:   RBX-2660: Clinical Trial Details for Recurrent C. diff. Infection (CDI)
Figure 27:   CH-106: Clinical Design for Metabolic Syndrome/Prediabetes
Figure 28:   Share of Key Developments and Strategies, January 2019–October 2021
Figure 29:   Share of Synergistic Activities (by Company), January 2019-October 2021
Figure 30:   Share of Product Launch and Regulatory Approvals (by Company), January 2019-October 2021
Figure 31:   Share of Funding and Investment (by Company), January 2019-October 2021
Figure 32:   Share of Mergers and Acquisitions (by Company), January 2019-October 2021
Figure 33:   Market Share Analysis for the Global Microbiome Therapeutics Market, $Million, 2020 and 2021
Figure 34:   Growth-Share Analysis (by Region), 2020-2021
Figure 35:   Growth-Share Analysis (by Company), 2020-2021
Figure 36:   Global Microbiome Therapeutics Market (by Target Therapy Area), $Million, 2021 and 2032
Figure 37:   Number of Pipeline Candidates for Gastrointestinal and Infectious Diseases
Figure 38:   Global Microbiome Therapeutics Market (Gastrointestinal and Infectious Diseases), $Million, 2021-2032
Figure 39:   Number of Pipeline Products for Skin Disorders
Figure 40:   Global Microbiome Therapeutics Market (Skin Disorders), $Million, 2021-2032
Figure 41:   Number of Pipeline Products for Cancer Indications
Figure 42:   Number of Pipeline Products for Other Indications
Figure 43:   Global Microbiome Therapeutics Market (by Region), 2022-2032
Figure 44:   Global Microbiome Therapeutics Market Share (by Region), $Million, 2021-2032
Figure 45:   North America Microbiome Therapeutics Market, $Million, 2021-2032
Figure 46:   North America: Market Dynamics
Figure 47:   North America Microbiome Therapeutics Market Share (by Country), $Million, 2021 and 2032
Figure 48:   U.S. Microbiome Therapeutics Market, $Million, 2021-2032
Figure 49:   Canada Microbiome Therapeutics Market, $Million, 2021-2032
Figure 50:   Europe Microbiome Therapeutics Market, $Million, 2021-2032
Figure 51:   Europe: Market Dynamics
Figure 52:   Europe Microbiome Therapeutics Market Share (by Country), $Million, 2021 and 2032
Figure 53:   France Microbiome Therapeutics Market, $Million, 2021-2032
Figure 54:   Germany Microbiome Therapeutics Market, $Million, 2021-2032
Figure 55:   Sweden Microbiome Therapeutics Market, $Million, 2021-2032
Figure 56:   U.K Microbiome Therapeutics Market, $Million, 2021-2032
Figure 57:   Italy Microbiome Therapeutics Market, $Million, 2021-2032
Figure 58:   Spain Microbiome Therapeutics Market, $Million, 2021-2032
Figure 59:   Rest-of-Europe Microbiome Therapeutics Market, $Million, 2021-2032
Figure 60:   Asia-Pacific Microbiome Therapeutics Market, $Million, 2021-2032
Figure 61:   Asia-Pacific: Market Dynamics
Figure 62:   Asia-Pacific Microbiome Therapeutics Market Share (by Country), $Million, 2021-2032
Figure 63:   Japan Microbiome Therapeutics Market, $Million, 2021-2032
Figure 64:   Australia Microbiome Therapeutics Market, $Million, 2021-2032
Figure 65:   China Microbiome Therapeutics Market, $Million, 2021-2032
Figure 66:   India Microbiome Therapeutics Market, $Million, 2021-2032
Figure 67:   Rest-of-Asia-Pacific Microbiome Therapeutics Market, $Million, 2021-2032
Figure 68:   Rest-of-the-World Microbiome Therapeutics Market, $Million, 2021-2032
Figure 69:   4D pharma plc: Product Portfolio
Figure 70:   4D pharma plc: Overall Financials, $Million, 2019-2021
Figure 71:   4D pharma plc: R&D Expenditure, $Million, 2019-2021
Figure 72:   Seres Therapeutics, Inc.: Product Portfolio
Figure 73:   Seres Therapeutics, Inc.: Overall Financials, $Million, 2019-2021
Figure 74:   Seres Therapeutics, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 75:   Microbiotica: Product Portfolio
Figure 76:   Enterome: Product Portfolio
Figure 77:   Destiny Pharma plc: Product Portfolio
Figure 78:   Destiny Pharma plc: Overall Financials, $Million, 2019-2021
Figure 79:   Destiny Pharma plc: R&D Expenditure, $Million, 2019-2021
Figure 80:   Taisho Pharmaceutical Holdings: Product Portfolio
Figure 81:   Taisho Pharmaceutical Holdings: Overall Financials, $Million, 2019-2021
Figure 82:   Taisho Pharmaceutical Holdings: Net Revenue (by Segment), $Million, 2019-2021
Figure 83:   Taisho Pharmaceutical Holdings: Net Revenue (by Region), $Million, 2019-2021
Figure 84:   Taisho Pharmaceutical Holdings: R&D Expenditure, $Million, 2019-2021
Figure 85:   AOBiome Therapeutics, Inc.: Product Portfolio
Figure 86:   Finch Therapeutics Group, Inc.: Product Portfolio
Figure 87:   Finch Therapeutics Group, Inc.: Overall Financials, $Million, 2019-2021
Figure 88:   Finch Therapeutics Group, Inc.: R&D Expenditure, $Million, 2020-2021
Figure 89:   Rebiotix Inc.: Product Portfolio
Figure 90:   MaaT Pharma: Product Portfolio
Figure 91:   MaaT Pharma: Overall Financials, $Million, 2020-2021
Figure 92:   MaaT Pharma: R&D Expenditure, $Million, 2020-2021
Figure 93:   Vedanta Biosciences Inc.: Product Portfolio
Figure 94:   OxThera AB: Product Portfolio
Figure 95:   Pendulum Therapeutics: Product Portfolio
Figure 96:   Caelus Health: Product Portfolio
Figure 97:   Quorum Innovations: Product Portfolio
Figure 98:   Sanofi S.A.: Product Portfolio
Figure 99:   Sanofi S.A.: Overall Financials, $Million, 2019-2021
Figure 100:   Sanofi S.A.: Net Revenue (by Segment), $Million, 2019-2021
Figure 101:   Sanofi S.A.: Net Revenue by Region), $Million, 2019-2021
Figure 102:   Sanofi S.A.: R&D Expenditure, $Million, 2019-2021
Figure 103:   DermBiont, Inc.: Product Portfolio
Figure 104:   EnteroBiotix Ltd: Product Portfolio
Figure 105:   YSOPIA Bioscience: Product Portfolio
Figure 106:   Winclove Probiotics: Product Portfolio
Figure 107:   TargEDys: Product Portfolio
Figure 108:   Evelo Biosciences, Inc.: Product Portfolio
Figure 109:   Evelo Biosciences, Inc.: Pipeline Products
Figure 110:   Evelo Biosciences, Inc.: Overall Financials, $Million, 2019-2021
Figure 111:   Evelo Biosciences, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 112:   BiomX: Product Portfolio
Figure 113:   BiomX: Pipeline Products
Figure 114:   BiomX: Overall Financials, $Million, 2019-2021
Figure 115:   BiomX: R&D Expenditure, $Million, 2019-2021
Figure 116:   Biomica Ltd.: Pipeline Product
Figure 117:   Scioto Biosciences, Inc.: Product Portfolio
Figure 118:   Scioto Biosciences, Inc.: Pipeline Product
Figure 119:   Lactobio A/S: Product Portfolio
Figure 120:   Lactobio A/S: Pipeline Product

Market Report Coverage

Global Microbiome Therapeutics Market
Base Year	2021	Market Size in 2021	$306.3 Million
Forecast Period	2022-2032	Value Projection and Estimation by 2032	$3,204.0 Million
CAGR During Forecast Period	24.95%	Number of Tables	33
Number of Pages	195	Number of Figures	120

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

The top segment players leading the market include Sanofi S.A and Taisho Pharmaceutical Holding that capture around 88% of the market with Sanofi S.A holding 64.31% while Taisho Pharmaceutical Holdings 24.49% respectively.

Some of the prominent established names in this market are:

•   4D pharma plc
•   Seres Therapeutics, Inc.
•   Microbiotica
•   Enterome
•   Enterome Biosciences
•   Destiny Pharma plc
•   Taisho Pharmaceutical Holdings
•   AOBiome Therapeutics, Inc.
•   Finch Therapeutics Group, Inc.
•   Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
•   MaaT Pharma
•   Vedanta Biosciences Inc.
•   OxThera AB
•   Pendulum Therapeutics
•   Caelus Health
•   Quorum Innovations
•   Sanofi S.A.
•   DermBiont, Inc.
•   EnteroBiotix Ltd
•   YSOPIA Bioscience
•   Winclove Probiotics
•   TargEDys
•   Evelo Biosciences, Inc.
•   BiomX
•   Biomica Ltd.
•   Scioto Biosciences, Inc.
•   Lactobio A/S

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The report provides an exhaustive list of pipeline products which are currently in the development along with their developmental details in various indications. This can help organizations in understanding the research activities, which is the promising indication to pursue or which organization has the potential product to enter first into the market as well it can help the organization to assess where should they place themselves in order to get maximum benefit.

Growth/Marketing Strategy: In addition to pursuing research on exploring the benefits of microbiome therapeutics for new indications, companies are evaluating next-generation-probiotics (NGPs) to address clinical conditions. Looking at the storage issues of microbiome therapeutics, companies are exploring extracellular vesicles as an alternative option. Furthermore, companies are working on increasing consumer awareness about Microbiome therapeutics and its potential benefits of being natural product containing live microorganism derived from human body as well as pursuing synergistic activities to bring an effective microbiome therapeutics for the affected population.

Competitive Strategy: Key players in the global microbiome therapeutics market were analyzed and profiled in the study, who are developing products containing live biotherapeutic products (LBPs), fecal microbiota transplantation (FMT) as well as next-generation-probiotics (NGPs). Moreover, a detailed competitive benchmarking of the players operating in the global microbiome therapeutics market has been done to help the reader understand how players stand against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Industry & Technology Overview

Market Overview

Microbiome therapeutics have drawn significant attention from the medical community with their potential to address the existing unmet need of various clinical conditions. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032.

The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market.

Impact of COVID-19

There were numerous consequences due to the COVID-19 pandemic, especially because of the reduced access to care for other illnesses. As the number of individuals becoming ill from COVID-19 kept increasing and for the protection of healthy individuals from being affected by the disease, all non-urgent healthcare facilities were suspended as per respective government directives. Even though these measures were necessary, it had mostly negative impact on the Global microbiome therapeutics market. Some the major impacts were; interruption of key clinical trial activities, modification of clinical trial guidelines bringing in additional safety measures, and delay in regulatory agencies’ review and approval timeline.

Market Segmentation:

Within the research report, the market is segmented on the basis of:

• target therapy area (gastrointestinal and infectious diseases, skin disorders, cancer indications, and other indications)
• region (North America, Europe, Asia-Pacific, and Rest-of-the-World).

This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.

Segmentation 1: by Target Therapy Area

Disorders related to gastrointestinal (GI) and skin disorders command a major share of the microbiome therapeutics segment, and is expected to continue during the forecast period. Most of the microbiome therapeutics in advanced development stage are indicated to treat C.diff. infection (CDI) and expected to enter the market first. The indications selected were on the basis of research intensity in the specific therapy area.

Segmentation 2: by Region

Asia-Pacific (APAC) is expected to dominate the global microbiome therapeutics market for the forecast period 2022-2032 continuuing with it overall contribution of approximately 40% of the total market size in 2021 followed by Europe with 32.59%. Increasing healthcare expenditure, coupled with government initiatives, are among the leading factors contributing to the growth of the market.

Demand – Drivers and Challenges

Some of the potential drivers identified by BIS Research includes:

•   Growing Strategic Activities in Microbiome Therapeutics Segment
•   Potential of Microbiome Therapeutics to Address Unmet Needs of Existing Treatment Options
•   Microbiome Therapeutic Products as a Safer Alternative to Conventional Drug Treatments

There are some challenges identified for the global microbiome therapeutics market are; Lack of standard regulatory guidelines and safety issues associated with live biotherapeutic products (LBPs).

Analyst Thoughts

According to Tausif, Principal Analyst, BIS Research, "Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The gastrointestinal and infectious diseases segment market is expected to increase due to the possible introduction of late-stage candidates exclusively developed for GI indications. It is anticipated that the positive findings from the ongoing clinical trials will serve as another shot for the segment to witness significant growth in the coming years.”